or Try an Advanced Search...

    Secondary Hyperparathyroidism Stocks List

    Symbol Grade Name % Change
    OPK A OPKO Health Inc. 1.23
    RMTI D Rockwell Medical, Inc. -5.42
    View As Page of Charts
    Related Industries: Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Chronic Kidney Disease Dialysis End Stage Renal Disease Hemodialysis Hyperparathyroidism Kidney Disease Organ Failure Phosphates Renal Disease Stage Renal Disease Thyroid Vitamins Acid Active Pharmaceutical Ingredients Alzheimer's Disease Antibiotics Asthma Autoimmune Disease Biomarkers Biopharmaceutical

    Related ETFs - A few ETFs which own one or more of the above listed Secondary Hyperparathyroidism stocks.

    Symbol Grade Name Weight
    PBE D PowerShares Dynamic Biotech & Genome 2.5
    OZEM F Roundhill GLP-1 & Weight Loss ETF 1.43
    XHS D SPDR S&P Health Care Services ETF 0.56
    QQQS C Invesco NASDAQ Future Gen 200 ETF 0.46
    THNR F Amplify Weight Loss Drug & Treatment ETF 0.21
    View all Secondary Hyperparathyroidism ETFs...
    Compare ETFs
    Compare OZEM to XHS Compare PBE to XHS Compare QQQS to THNR

        Secondary Hyperparathyroidism Stocks Recent News

        Date Stock Title
        Nov 16 OPK Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors
        Nov 14 OPK NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results
        Nov 14 RMTI Time To Worry? Analysts Just Downgraded Their Rockwell Medical, Inc. (NASDAQ:RMTI) Outlook
        Nov 13 RMTI This microcap healthcare stock could double in value by 2027, analyst says
        Nov 13 RMTI Rockwell Medical's Dip Gives A Speculative Opportunity
        Nov 13 RMTI Rockwell Medical Inc (RMTI) Q3 2024 Earnings Call Highlights: Record Growth and Strategic ...
        Nov 13 RMTI Q3 2024 Rockwell Medical Inc Earnings Call
        Nov 12 RMTI Rockwell Medical, Inc. (RMTI) Q3 2024 Earnings Call Transcript
        Nov 12 RMTI Rockwell Medical (RMTI) Surpasses Q3 Earnings and Revenue Estimates
        Nov 12 RMTI Rockwell Medical: Q3 Earnings Snapshot
        Nov 12 RMTI Rockwell Medical Non-GAAP EPS of $0.09, revenue of $28.32M beats by $1.82M
        Nov 12 RMTI Rockwell Medical Reports Third Quarter 2024 Earnings, Generates Profitability on a Cash Flow and Adjusted EBITDA Basis for the Second Consecutive Quarter
        Nov 12 RMTI Earnings Scheduled For November 12, 2024
        Nov 11 OPK Phillip Frost Buys Handful Of Shares In OPKO Health
        Related Industries: Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Chronic Kidney Disease Dialysis End Stage Renal Disease Hemodialysis Hyperparathyroidism Kidney Disease Organ Failure Phosphates Renal Disease Stage Renal Disease Thyroid Vitamins Acid Active Pharmaceutical Ingredients Alzheimer's Disease Antibiotics Asthma Autoimmune Disease Biomarkers Biopharmaceutical
        Secondary Hyperparathyroidism

        Secondary hyperparathyroidism is a condition in which the parathyroid glands become overactive due to an underlying medical condition. This overactivity leads to an increase in the production of parathyroid hormone (PTH), which can cause an increase in calcium levels in the blood. Common causes of secondary hyperparathyroidism include chronic kidney disease, vitamin D deficiency, and certain medications. Symptoms of secondary hyperparathyroidism may include fatigue, bone pain, and increased risk of fractures. Treatment typically involves addressing the underlying cause and may include medications, dietary changes, and/or surgery.

        Browse All Tags